<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PRF</journal-id>
<journal-id journal-id-type="hwp">spprf</journal-id>
<journal-id journal-id-type="nlm-ta">Perfusion</journal-id>
<journal-title>Perfusion</journal-title>
<issn pub-type="ppub">0267-6591</issn>
<issn pub-type="epub">1477-111X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0267659112457970</article-id>
<article-id pub-id-type="publisher-id">10.1177_0267659112457970</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A pilot study comparing two polymethylpentene extracorporeal membrane oxygenators</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Rambaud</surname><given-names>J</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Guilbert</surname><given-names>J</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Guellec</surname><given-names>I</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Renolleau</surname><given-names>S</given-names></name>
</contrib>
<aff id="aff1-0267659112457970">Paediatric Intensive Care Unit, Armand-Trousseau Children’s Hospital APHP (Paris Hospitals Public Assistance) UPMC (Pierre and Marie Curie University, Paris VI) Paris, France</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0267659112457970">Sylvain Renolleau Paediatric Intensive Care Unit Armand-Trousseau Children’s Hospital APHP (Paris Hospitals Public Assistance) Paris, France Email: <email>sylvain.renolleau@trs.aphp.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>1</issue>
<fpage>14</fpage>
<lpage>20</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0267659112457970">
<title>Objective:</title>
<p>We compared two polymethylpentene oxygenators being used in our unit: the Maquet Quadrox-iD paediatric® and the Medos Hilite 800LT®.</p>
</sec>
<sec id="section2-0267659112457970">
<title>Study design:</title>
<p>A mono-centric, prospective pilot study was conducted on ten consecutive newborn patients who had been admitted to our hospital service for extracorporeal circulation (EC) treatment. We examined the rate of oxygen transfer, the CO<sub>2</sub> removal capacity and the average sweep gas flow required to produce this result. We also assessed the disturbances of haemostasis, the need for labile blood products and the membrane oxygenator lifetime and cost of use.</p>
</sec>
<sec id="section3-0267659112457970">
<title>Conclusions:</title>
<p>According to our study, it seems to us that Medos Hilite 800LT® membrane oxygenators demonstrate greater oxygen transfer and CO<sub>2</sub> removal capacity than Maquet Quadrox-iD paediatric® membrane oxygenators, at a similar cost. These results lead us to conclude that it is reasonable to continue using Medos Hilite 800LT® membrane oxygenators. A broader comparison study would be necessary in order to support these initial results.</p>
</sec>
</abstract>
<kwd-group>
<kwd>extracorporeal circulation</kwd>
<kwd>polymethylpentene membrane</kwd>
<kwd>efficiency</kwd>
<kwd>neonatal</kwd>
<kwd>cost study</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section4-0267659112457970" sec-type="intro">
<title>Introduction</title>
<p>Extracorporeal circulation (EC) techniques are used as a last resort during paediatric resuscitation in the case of persistent refractory hypoxaemia under maximum mechanical ventilation and during the use of all so-called conventional therapies.<sup><xref ref-type="bibr" rid="bibr1-0267659112457970">1</xref><xref ref-type="bibr" rid="bibr2-0267659112457970"/><xref ref-type="bibr" rid="bibr3-0267659112457970"/>-<xref ref-type="bibr" rid="bibr4-0267659112457970">4</xref></sup> These techniques can lead to complications, such as haemorrhaging, thromboembolism or oxygenator failure.<sup><xref ref-type="bibr" rid="bibr5-0267659112457970">5</xref><xref ref-type="bibr" rid="bibr6-0267659112457970"/><xref ref-type="bibr" rid="bibr7-0267659112457970"/>-<xref ref-type="bibr" rid="bibr8-0267659112457970">8</xref></sup> The superiority of polymethylpentene (PMP) membrane oxygenators in relation to silicone membrane has been previously demonstrated.<sup><xref ref-type="bibr" rid="bibr9-0267659112457970">9</xref>,<xref ref-type="bibr" rid="bibr10-0267659112457970">10</xref></sup> Recent in vitro studies have attempted to show the differences between several different models of polymethylpentene EC membrane oxygenators.<sup><xref ref-type="bibr" rid="bibr11-0267659112457970">11</xref></sup> However, no in vivo study aiming to compare different polymethylpentene EC membrane oxygenators has been carried out. The issue today consists in improving our techniques (with regard to the types of membrane oxygenators, pumps and cannulae being used) in order to reduce the number of serious complications and the overall costs.<sup><xref ref-type="bibr" rid="bibr12-0267659112457970">12</xref></sup></p>
<p>The objective of our study, therefore, was to compare two PMP oxygenators widely used in our unit in order to determine whether or not one of them was superior for use in long-term EC treatments.</p>
</sec>
<sec id="section5-0267659112457970" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section6-0267659112457970">
<title>Study design</title>
<p>From November 2010 to May 2011, we carried out a mono-centric, prospective study on newborn patients hospitalized for EC treatment in the paediatric resuscitation unit at Armand-Trousseau Children’s Hospital. The type of EC treatment to be administered (venovenous EC with single or double cannulae, or venoarterial EC) was determined according to each child’s pathology. The membrane oxygenators used were the Medos Hilite 800LT® (Medos Medizintechnik AG, Stolberg, Germany) and the Maquet Quadrox-iD paediatric® (Maquet Cardiovascular, Hirrlingen, Germany). The main differences between these two types of membrane oxygenators lie in their conformation, their surface and their cost (<xref ref-type="table" rid="table1-0267659112457970">Table 1</xref>). The pumps used in the course of the study were pumps with distensible tubes (Sofracob®) which work with an alternative clamp for EC treatment with a venovenous single cannula (AREC/extracorporeal respiratory support).<sup><xref ref-type="bibr" rid="bibr13-0267659112457970">13</xref></sup></p>
<table-wrap id="table1-0267659112457970" position="float">
<label>Table 1.</label>
<caption>
<p>Characteristics of the two oxygenators</p>
</caption>
<graphic alternate-form-of="table1-0267659112457970" xlink:href="10.1177_0267659112457970-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">HILITE 800®</th>
<th align="left">QUADROX-iD®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum blood flow</td>
<td>0.8 L/min</td>
<td>2.8 L/min</td>
</tr>
<tr>
<td>Maximum gas flow</td>
<td>1.6L/min</td>
<td>5.6L/min</td>
</tr>
<tr>
<td>Fill volume</td>
<td>55 ml</td>
<td>81 ml</td>
</tr>
<tr>
<td><bold>Oxygenator</bold></td>
<td/>
<td/>
</tr>
<tr>
<td>Materials</td>
<td>Polymethylpentene</td>
<td>Polymethylpenene</td>
</tr>
<tr>
<td>Surface</td>
<td>0.32 m 2</td>
<td>0.8 m 2</td>
</tr>
<tr>
<td><bold>Heat exchanger</bold></td>
<td>Included</td>
<td>Included</td>
</tr>
<tr>
<td>Surface</td>
<td>0.074 m2</td>
<td>0.15 m 2</td>
</tr>
<tr>
<td><bold>Connectors</bold></td>
<td/>
<td/>
</tr>
<tr>
<td>Blood entrance and exit</td>
<td>3/16-1/4</td>
<td>1/4</td>
</tr>
<tr>
<td>Gas entrance and exit</td>
<td>1/4</td>
<td>1/4 (entrance) and 3/8 (exit)</td>
</tr>
<tr>
<td>Need for de-bubbling</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section7-0267659112457970">
<title>Statistics</title>
<p>All of the statistics cited in this study were produced through a Wilcoxon rank-sum (Mann-Whitney) unpaired test. The significance level was set at p&lt;0.05. Meanwhile, we also produced a set of statistics using a Wilcoxon signed-rank paired difference test.</p>
</sec>
<sec id="section8-0267659112457970">
<title>Patients</title>
<p>Ten consecutive patients were prospectively included in this study. Over the course of the study, nine Medos Hilite 800LT® membrane oxygenators and ten Maquet Quadrox-iD paediatric® membrane oxygenators were used. Both types of membrane oxygenators were used on six of our patients undergoing EC treatment. At the time of the connection to the circuit, the selection of the type of membrane oxygenator to be used was randomized. After the initial connection, a different type of membrane oxygenator was used for each EC circuit change. We chose to replace the oxygenator of one brand by the other brand to avoid a “patient effect” on the lifetime of the oxygenator and the need for blood products The characteristics of these patients are presented in <xref ref-type="table" rid="table2-0267659112457970">Table 2</xref>.</p>
<table-wrap id="table2-0267659112457970" position="float">
<label>Table 2.</label>
<caption>
<p>Characteristics of the population studied</p>
</caption>
<graphic alternate-form-of="table2-0267659112457970" xlink:href="10.1177_0267659112457970-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">HILITE 800®</th>
<th align="left">QUADROX-iD®</th>
<th align="left">p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boys/girls</td>
<td>4/4</td>
<td>4/4</td>
<td>1</td>
</tr>
<tr>
<td>Average age (d)</td>
<td>8 ± 9</td>
<td>8 ± 9</td>
<td>1</td>
</tr>
<tr>
<td>Average weight (kg)</td>
<td>3.2 ± 0.4</td>
<td>3.4 ± 0.7</td>
<td>1</td>
</tr>
<tr>
<td>Average AaDO<sub>2</sub></td>
<td>583 ± 40</td>
<td>581 ± 43</td>
<td>1</td>
</tr>
<tr>
<td>Average OI</td>
<td>39 ± 17</td>
<td>41 ± 17</td>
<td>1</td>
</tr>
<tr>
<td>Average PaO<sub>2</sub>/FiO<sub>2</sub></td>
<td>40 ± 10</td>
<td>41 ± 14</td>
<td>1</td>
</tr>
<tr>
<td>Average ventilation index</td>
<td>102 ± 41</td>
<td>94 ± 47</td>
<td>0.9</td>
</tr>
<tr>
<td>Average PaCO<sub>2</sub></td>
<td>72 ± 28</td>
<td>83 ± 34</td>
<td>0.87</td>
</tr>
<tr>
<td>Nitric oxide</td>
<td>8/8</td>
<td>8/8</td>
<td>1</td>
</tr>
<tr>
<td>Haemodynamic disorders</td>
<td>7/8</td>
<td>8/8</td>
<td>1</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0267659112457970">
<p>AaDO<sub>2</sub>:Alveolar-arterial oxygen tension difference; FiO<sub>2</sub>: Fraction of inspired oxygen; OI: Oxygen Index;</p>
</fn>
<fn id="table-fn2-0267659112457970">
<p>PaCO<sub>2</sub> Partial pressure of arterial CO<sub>2</sub>; PaO<sub>2</sub>: Partial pressure of oxygen.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0267659112457970">
<title>Methods</title>
<p>The criteria for EC treatment were established according to the value of the oxygenation index, the alveolar-arterial difference for oxygen (AaD-O<sub>2</sub>) and the PaO<sub>2</sub>/FiO<sub>2</sub> ratio.<sup><xref ref-type="bibr" rid="bibr14-0267659112457970">14</xref>,<xref ref-type="bibr" rid="bibr15-0267659112457970">15</xref></sup> The rates of oxygen transfer (PaO<sub>2</sub> at the membrane inlet; PaO<sub>2</sub> at the membrane outlet) and CO<sub>2</sub> removal capacity (PaCO<sub>2</sub> at the membrane outlet; PaCO<sub>2</sub> at the membrane inlet) were conducted with an FiO<sub>2</sub> of 100%. The PaO<sub>2</sub> measurements were carried out at the same blood flow rate and the same haemoglobin levels. The established objectives were to obtain normal blood pH with a PaCO<sub>2</sub> of 40-50 mmHg at the membrane inlet. Where there was complete respiratory support, the goal for venous saturation was 65-75% for venoarterial EC and 75-85% for venovenous EC with double cannulae. We also assessed the membrane oxygenator resistance through the pressure differential at the membrane oxygenator inlet and the membrane oxygenator outlet. The resistance corresponds to the pressure loss between the membrane oxygenator inlet and the membrane oxygenator outlet. The average sweep gas flow needed to obtain these results was also examined.</p>
<p>In order to assess the haemostasis disturbances, the levels of platelets, fibrinogen, D-dimers, activated clotting time (ACT) and anti-Xa were analysed. Our goals with regard to anticoagulation were to obtain ACT levels that would be three times higher than the norm and anti-Xa levels of 0.3-0.5 IU/ml.<sup><xref ref-type="bibr" rid="bibr16-0267659112457970">16</xref></sup> Coagulation was monitored every four hours by means of the Hemochron test (Terumo, Essen, Germany). The goal was to have coagulation between 180 and 200 for venovenous EC and between 200 and 220 for venoarterial EC. Before connecting the patient to the circuit, the levels of free and functionally active protein S, of functionally active protein C and of antithrombin III were measured in order to eliminate any congenital disorders of haemostasis which could have interfered with the results.</p>
<p>The blood product needs were assessed through the quantification of the packed red blood cells and platelet concentrates being used per day of EC treatment. The transfusion thresholds were established before the beginning of the study. Levels of 10 g/dl of haemoglobin and 60,000 platelets/mm<sup>3</sup> are customary.<sup><xref ref-type="bibr" rid="bibr17-0267659112457970">17</xref>-<xref ref-type="bibr" rid="bibr18-0267659112457970">18</xref></sup> Whenever the haemoglobin levels were lower than 10 g/dl, a volume of 40 ml/kg of packed red blood cells was transfused, taking into account the child’s blood volume and that of the EC circuit. Any decisions to discontinue EC treatment were based on the patient’s capacity to maintain stable haemodynamics, as well as efficient CO<sub>2</sub> removal (PaCO<sub>2</sub> of 40-50 mmHg) and efficient oxygenation with minimum support or whenever haemodynamic or neurological developments in the patient made it impossible to contemplate permanent weaning from the EC treatment.</p>
<p>The patients were monitored right up to their release from the resuscitation unit and information on any complications was collected: cerebral haemorrhaging, cerebrovascular accidents (CVAs) or death.</p>
<p>In order to assess the cost per day of the two membrane being tested, we took into account the cost of labile blood products as established by annual decree (€ 112.70 per packed blood cell and € 76.06 per platelet unit) as well as the cost of the membranes themselves.</p>
</sec>
</sec>
<sec id="section10-0267659112457970" sec-type="results">
<title>Results</title>
<sec id="section11-0267659112457970">
<title>Patient randomisation and protocol</title>
<p>Patient characteristics at the time of connection to the EC circuit and the indications for connection to extracorporeal circulation were similar in the two groups (<xref ref-type="table" rid="table2-0267659112457970">Tables 2</xref> and <xref ref-type="table" rid="table3-0267659112457970">3</xref>).</p>
<table-wrap id="table3-0267659112457970" position="float">
<label>Table 3.</label>
<caption>
<p>EC connection information for each patient</p>
</caption>
<graphic alternate-form-of="table3-0267659112457970" xlink:href="10.1177_0267659112457970-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Patient 1</td>
<td>Malignant pertussis</td>
</tr>
<tr>
<td>Patient 2</td>
<td>Meconium inhalation, PAH</td>
</tr>
<tr>
<td>Patient 3</td>
<td>Meconium inhalation, PAH</td>
</tr>
<tr>
<td>Patient 4</td>
<td>Diaphragmatic hernia, PAH</td>
</tr>
<tr>
<td>Patient 5</td>
<td>Meconium inhalation, PAH</td>
</tr>
<tr>
<td>Patient 6</td>
<td>Diaphragmatic hernia, PAH</td>
</tr>
<tr>
<td>Patient 7</td>
<td>Septic shock</td>
</tr>
<tr>
<td>Patient 8</td>
<td>Meconium inhalation, PAH</td>
</tr>
<tr>
<td>Patient 9</td>
<td>Septic shock</td>
</tr>
<tr>
<td>Patient 10</td>
<td>Meconium inhalation, PAH, HCM</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0267659112457970">
<p>PAH: pulmonary arterial hypertension; HCM: hypertrophic cardiomyopathy</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0267659112457970">
<title>Oxygenator efficiency</title>
<p><italic>Oxygenation</italic>: The rate of oxygen transfer per m<sup>2</sup> was significantly better in Medos Hilite 800LT® membrane oxygenators (oxygenation capacity/surface ratios [SD] were 1138 [307] and 538 [115] mmHg per m<sup>2</sup> for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p&lt;0.0001).</p>
<p><italic>CO</italic><sub><italic>2</italic></sub> <italic>Removal</italic>: The Medos Hilite 800LT® membrane oxygenators had a greater removal capacity per m<sup>2</sup> (the removal capacity/sweep gas flow/surface ratios [SD] were 0.038 [0.004] and 0.022 [0.001] mmHg/ml/mn/m<sup>2</sup> for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p&lt;0.0001). However, the ratio for CO<sub>2</sub> removal capacity and sweep gas flow was significantly higher for the Maquet Quadrox-iD paediatric® membrane oxygenators (the CO<sub>2</sub> removal capacity/sweep gas flow ratios [SD] were 0.012 [0.001] and 0.02 [0.002] mmHg/ml/mn for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.01).</p>
<p>The CO<sub>2</sub> removal capacity and the oxygen transfer rate at the membrane oxygenator surface were significantly better in the Medos Hilite 800LT® membrane oxygenators (<xref ref-type="table" rid="table4-0267659112457970">Table 4</xref>).</p>
<table-wrap id="table4-0267659112457970" position="float">
<label>Table 4.</label>
<caption>
<p>Membrane efficiency</p>
</caption>
<graphic alternate-form-of="table4-0267659112457970" xlink:href="10.1177_0267659112457970-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">HILITE 800LT® (average/standard deviation)</th>
<th align="left">QUADROX-iD ® (average/standard deviation)</th>
<th align="left">p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygenation capacity (mmHg)</td>
<td>363 ± 92</td>
<td>436 ± 97</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Oxygenation capacity / surface ratio (mmHg/m<sup>2</sup>)</td>
<td>1138 ± 307</td>
<td>538 ± 115</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>CO<sub>2</sub> removal capacity (mmHg)</td>
<td>14.49 ± 6</td>
<td>14.45 ± 4</td>
<td>0.88</td>
</tr>
<tr>
<td>CO<sub>2</sub> removal capacity / sweep gas flow ratio (mmHg/ml/mn)</td>
<td>0.012 ± 0.001</td>
<td>0.02 ± 0.002</td>
<td>0.01</td>
</tr>
<tr>
<td>CO<sub>2</sub> removal capacity / sweep gas flow /surface ratio (mmHg/ml/mn/m<sup>2</sup>)</td>
<td>0.038 ± 0.004</td>
<td>0.022 ± 0.001</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Average sweep gas flow (ml)</td>
<td>1400 ± 592</td>
<td>1003 ± 394</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Membrane resistance (mmHg)</td>
<td>16.7 ± 20</td>
<td>11.4 ± 7</td>
<td>0.06</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section13-0267659112457970">
<title>Oxygenator pressure and resistance</title>
<p>There was no significant difference in membrane oxygenator resistance (the average resistance [SD] was 16.7 [20] and 11.4 [7] mmHg for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.06).</p>
</sec>
<sec id="section14-0267659112457970">
<title>Coagulation data and consumption of blood products</title>
<p>The fibrinogen concentration was not significantly different (the fibrinogen concentration [SD] was 2.9 [0.7] and 2.8 [0.9] g/l for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.89). The D-dimer concentration was similar in both membrane oxygenators (D-dimer concentrations [SD] were 17.6 [16] and 17 [7.6] µg/l for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.76). The medium need for heparin was comparable in the two membrane oxygenators (the medium dose of heparin [SD] was 36 [7.3] and 35 [8.7] U/kg/h for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.5). These results suggest that, with regard to haemostasis disturbances linked to extracorporeal circulation, there is no difference in the two membrane oxygenators. In just half the cases, the haemostasis evaluation was conducted prior to connection to the EC circuit in search of haemostasis anomalies. No anomalies were found.</p>
<p>There was no significant difference in the consumption of packed red blood cells and platelet concentrates (the average daily consumption of packed red blood cells [SD] was 0.23 [0.12] and 0.18 [0.12] for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.38 and the average daily consumption of platelet concentrates [SD] was 0.67 [0.29] and 0.76 [0.30] for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.38) (<xref ref-type="table" rid="table5-0267659112457970">Table 5</xref>).</p>
<table-wrap id="table5-0267659112457970" position="float">
<label>Table 5.</label>
<caption>
<p>Membranes and haemostasis disorders</p>
</caption>
<graphic alternate-form-of="table5-0267659112457970" xlink:href="10.1177_0267659112457970-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">HILITE 800LT ®</th>
<th align="left">QUADROX-iD®</th>
<th align="left">P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average fibrinogen concentration (g/l)</td>
<td>2.9 ± 0.7</td>
<td>2.8 ± 0.9</td>
<td>0.89</td>
</tr>
<tr>
<td>D-dimers concentration (mg/ml)</td>
<td>17.6 ± 16</td>
<td>15 ± 7.6</td>
<td>0.76</td>
</tr>
<tr>
<td>Average heparin (U/kg/h)</td>
<td>36 ± 7.3</td>
<td>35 ± 8.7</td>
<td>0.8</td>
</tr>
<tr>
<td>Daily aphaeresis consumption</td>
<td>0.67</td>
<td>0.76</td>
<td>0.58</td>
</tr>
<tr>
<td>Daily erythrocyte concentrate consumption</td>
<td>0.23 ± 0.12</td>
<td>0.18 ± 0.12</td>
<td>0.38</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Without considering the type of oxygenator, there was also no significant difference in the consumption of packed red blood cells and platelet concentrate (excepting patient N<sup>o</sup> 8 who consumed more platelets, but this patient used both devices in equal ways and didn’t alter the result) (data not shown).</p>
</sec>
<sec id="section15-0267659112457970">
<title>Consumption and cost of oxygenators</title>
<p>In the course of the study, we used a total of 19 membrane oxygenators: nine Medos Hilite 800LT® devices and ten Maquet Quadrox-iD paediatric® devices (Table 6). We made nine membrane oxygenator replacements, four of which were made for patient N° 8 alone. The average duration of the EC treatment was 15.7 days.</p>
<p>The average membrane oxygenator lifetime was not significantly different between the two devices (the average lifetime [SD] was 8.6 [6] and 11.1 [4.4] for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.40). If we exclude patients N°7 and N°10, for whom the EC treatment was discontinued, either because the patient quickly achieved independence (patient N°7) or because the patient died (N°10), the membrane lifetimes were still not significantly different (the average membrane oxygenator lifetime [SD] was 9.1 days [6.3] and 11.86 days [4.4] for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.44). Given the small number of patients, making a statement of fact of these results is difficult.</p>
<p>The assessment of the daily costs of EC with regard to the type of membrane oxygenator used and the cost of the labile blood products consumed did not reveal any significant difference (the average daily costs [SD] were € 184.53 [51] and € 214.34 [58] for the Medos Hilite 800LT® versus the Maquet Quadrox-iD paediatric®, p=0.38). The test did not reveal a specific duration after which one of the two membrane oxygenators became more attractive in terms of costs (<xref ref-type="fig" rid="fig1-0267659112457970">Figure 1</xref>).</p>
<fig id="fig1-0267659112457970" position="float">
<label>Figure 1.</label>
<caption>
<p>ROC curve comparing the daily costs of each membrane during its usage Red curve: daily costs for QUADROX-iD® membranes; Blue curve: daily costs for HILITE 800LT ® membranes</p>
</caption>
<graphic xlink:href="10.1177_0267659112457970-fig1.tif"/></fig>
</sec>
<sec id="section16-0267659112457970">
<title>Survival outcome</title>
<p>There was no significant difference in the survival and complication rates for the two membrane oxygenators.</p>
</sec>
</sec>
<sec id="section17-0267659112457970" sec-type="discussion">
<title>Discussion</title>
<p>This prospective pilot study enabled us to demonstrate a better oxygen transfer rate and a better CO<sub>2</sub> removal capacity in Medos Hilite 800LT® membrane oxygenators when the surface area was taken into consideration.</p>
<p>The oversizing of the Maquet Quadrox-iD paediatric® membrane oxygenator in relation to the corporeal surface of our newborn patients was not negligible and it led to a greater priming volume of 30 ml (10 ml/kg on average) which, consequently, led to an increase in the initial cost of labile blood products. We were particularly interested in studying the lifetime of our membrane oxygenators because we conduct long-term EC treatments with respiratory support. Our study shows that the lifetime of the Maquet Quadrox-iD paediatric® membrane oxygenators seems greater than that of the Medos Hilite 800LT® membrane oxygenators, though not significantly, and at a greater cost. The study did not reveal a delay of use from which a membrane cost less than the other one.</p>
<p>The small number of patients limits the impact of this study. Furthermore, membrane oxygenator lifetime may be affected by certain incidents that are characteristic of studies in vivo. In patient N°8, for instance, the extracorporeal connection time was long because of a technical difficulty in inserting the cannula into the internal jugular vein, which prolonged the use of the membrane oxygenator in closed circuit before connection. Such prolonged use of the membrane oxygenator in closed circuit increases the risk of premature coagulation in the membrane oxygenator, despite the administration of a loading dose of heparin when the circuit is implemented. Indeed, the Maquet Quadrox-iD paediatric® membrane oxygenator coagulated after two days of use. This incident probably skewed the calculation of the membrane oxygenator lifetime and daily cost: the cost of the Maquet Quadrox-iD paediatric® membrane oxygenator is far higher than that of the Medos Hilite 800LT® membrane oxygenator (€ 1000 before taxes versus € 450 before taxes). The amount of time needed for the cannulation procedure is different for each patient and, if it is protracted, may be responsible for premature coagulation in the membrane oxygenator.<sup><xref ref-type="bibr" rid="bibr19-0267659112457970">19</xref><xref ref-type="bibr" rid="bibr20-0267659112457970"/>-<xref ref-type="bibr" rid="bibr21-0267659112457970">21</xref></sup></p>
<p>Moreover, the pre-connection haemostasis evaluation was not conducted on all of the patients. It, therefore, does not allow us to formally rule out the possibility that pre-existing haemostasis disorders might lead to a greater consumption of blood products, greater need for heparin or premature coagulation in the EC membrane oxygenator. In a retrospective study carried out on 20 patients, Vats et al.<sup><xref ref-type="bibr" rid="bibr22-0267659112457970">22</xref></sup> examined the median hospital stay costs generated in paediatric EC, with the assumption that patients who survived after being released from hospital went on to enjoy a normal lifespan. Their calculations showed a cost of $ 4190 (€ 3331) per year of life saved. It seemed to us that it was relevant to study this cost criterion in the evaluation of the two membranes we were comparing.</p>
<p>Our study did not demonstrate any significant difference in the cost of use between the two membrane oxygenators, even though the Medos Hilite 800LT® membrane oxygenator seems to be less expensive.</p>
<p>Rather than the centrifugal pumps that are more commonly used today, we used EC pumps with distensible tubes.<sup><xref ref-type="bibr" rid="bibr23-0267659112457970">23</xref>,<xref ref-type="bibr" rid="bibr24-0267659112457970">24</xref></sup> Indeed, these are the only types of pumps that can be used for EC treatment with a venovenous single cannula (AREC/extracorporeal respiratory support). In our experience, there is no difference between centrifugal and extensible concerning the consumption of platelet units and packed red blood cells. Improvement in centrifugal pumps has enhanced the limitation of haemolysis. <sup><xref ref-type="bibr" rid="bibr25-0267659112457970">25</xref></sup></p>
<p>There is currently no single and 100% reliable means of monitoring the quality of anti-coagulation in patients. In order to balance anti-coagulation in our patients undergoing EC treatment, our unit simultaneously monitors several parameters: a twice-daily measurement of ACT and anti-Xa levels, as well as a Hemochron test (rapid measurement of the ACT) every four hours. Our practice is similar to what is recommended in the literature today<sup><xref ref-type="bibr" rid="bibr26-0267659112457970">26</xref><xref ref-type="bibr" rid="bibr27-0267659112457970"/>-<xref ref-type="bibr" rid="bibr28-0267659112457970">28</xref></sup>. Thus, we did not modify the membrane oxygenator lifetime by using any protocols or non-recommended methods for monitoring the rate of anticoagulation.</p>
<p>Today, the tendency is to reduce the size of the circuits and of the EC membrane oxygenators<sup><xref ref-type="bibr" rid="bibr29-0267659112457970">29</xref></sup> and there is some thought being put into the costs generated by such techniques. In light of these preliminary results, it seems reasonable to continue using the Medos Hilite 800LT® membrane oxygenators, which have a lower priming volume, a better oxygenation and CO<sub>2</sub> removal capacity at the membrane surface and a lower purchasing cost.</p>
<p>However, the power of our study is not sufficient to conclude definitively on the superiority of either of the two membranes. Both devices are efficient and any preference should be based on the specifics of the patient. It would be useful to realize a large randomized study to eliminate potential biases associated with the patient.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of Interest Statement</label>
<p>The authors have no conflicts of interest to declare</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0267659112457970">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khan</surname><given-names>S</given-names></name>
<name><surname>Vasavada</surname><given-names>R</given-names></name>
<name><surname>Qiu</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Extracorporeal life support systems: alternative vs. conventional circuits</article-title>. <source>Perfusion</source> <year>2011</year>; <volume>26</volume>: <fpage>191</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr2-0267659112457970">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skinner</surname><given-names>SC</given-names></name>
<name><surname>Hirschl</surname><given-names>RB</given-names></name>
<name><surname>Bartlett</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Extracorporeal life support</article-title>. <source>Semin Pediatr Surg</source> <year>2006</year>; <volume>15</volume>: <fpage>242</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr3-0267659112457970">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lequier</surname><given-names>L</given-names></name>
</person-group>. <article-title>Extracorporeal life support in paediatric and neonatal critical care: a review</article-title>. <source>J Intensive Care Med</source> <year>2004</year>; <volume>19</volume>: <fpage>243</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr4-0267659112457970">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mugford</surname><given-names>M</given-names></name>
<name><surname>Elbourne</surname><given-names>D</given-names></name>
<name><surname>Field</surname><given-names>D</given-names></name>
</person-group>. <article-title>Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants</article-title>. <source>Cochrane Database Syst Rev</source> <year>2008</year>; <volume>16</volume>: <fpage>CD001340</fpage>.</citation>
</ref>
<ref id="bibr5-0267659112457970">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oliver</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Anticoagulation and coagulation management for ECMO</article-title>. <source>Semin Cardiothorac Vasc Anesth</source> <year>2009</year>; <volume>13</volume>: <fpage>154</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr6-0267659112457970">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niebler</surname><given-names>RA</given-names></name>
<name><surname>Punzalan</surname><given-names>RC</given-names></name>
<name><surname>Marchan</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation</article-title>. <source>Pediatr Crit Care Med</source> <year>2010</year>; <volume>11</volume>: <fpage>98</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr7-0267659112457970">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hervey-Jumper</surname><given-names>SL</given-names></name>
<name><surname>Annich</surname><given-names>GM</given-names></name>
<name><surname>Yancon</surname><given-names>AR</given-names></name>
<etal/>
</person-group>. <article-title>Neurological complications of extracorporeal membrane oxygenation in children</article-title>. <source>J Neurosurg Pediatr</source> <year>2011</year>; <volume>7</volume>: <fpage>338</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr8-0267659112457970">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kao</surname><given-names>LS</given-names></name>
<name><surname>Fleming</surname><given-names>GM</given-names></name>
<name><surname>Escamilla</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. <article-title>Antimicrobial prophylaxis and infection surveillance in extracorporeal membrane oxygenation patients: a multi-institutional survey of practice patterns</article-title>. <source>ASAIO J</source> <year>2011</year>; <volume>57</volume>: <fpage>231</fpage>–<lpage>238</lpage></citation>
</ref>
<ref id="bibr9-0267659112457970">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khoshbin</surname><given-names>E</given-names></name>
<name><surname>Roberts</surname><given-names>N</given-names></name>
<name><surname>Harvey</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Poly-methyl pentene oxygenators have improved gas exchange capability and reduced transfusion requirements in adult extracorporeal membrane oxygenation</article-title>. <source>ASAIO J</source> <year>2005</year>; <volume>51</volume>: <fpage>281</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr10-0267659112457970">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khoshbin</surname><given-names>E</given-names></name>
<name><surname>Westrope</surname><given-names>C</given-names></name>
<name><surname>Pooboni</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators</article-title>. <source>Perfusion</source> <year>2005</year>; <volume>20</volume>: <fpage>129</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr11-0267659112457970">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Talor</surname><given-names>J</given-names></name>
<name><surname>Yee</surname><given-names>S</given-names></name>
<name><surname>Rider</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Comparaison of perfusion quality in hollow-fiber membrane oxygenators for neonatal extracorporeal life support</article-title>. <source>Artif Organs</source> <year>2010</year>; <volume>34</volume>: <fpage>E110</fpage>–<lpage>116</lpage></citation>
</ref>
<ref id="bibr12-0267659112457970">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crow</surname><given-names>S</given-names></name>
<name><surname>Fischer</surname><given-names>AC</given-names></name>
<name><surname>Schears</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Extracorporeal life support: utilization, cost, controversy, and ethics of trying to save lives</article-title>. <source>Semin Cardiothorac Vasc Anesth</source> <year>2009</year>; <volume>13</volume>: <fpage>183</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr13-0267659112457970">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chevalier</surname><given-names>JY</given-names></name>
<name><surname>Durandy</surname><given-names>Y</given-names></name>
<name><surname>Batisse</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Preliminary report: extracorporeal lung support for neonatal acute respiratory failure</article-title>. <source>Lancet</source> <year>1990</year>; <volume>335</volume>: <fpage>1364</fpage>–<lpage>1366</lpage>.</citation>
</ref>
<ref id="bibr14-0267659112457970">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krummel</surname><given-names>TM</given-names></name>
<name><surname>Greenfield</surname><given-names>LJ</given-names></name>
<name><surname>Kirkpatrick</surname><given-names>BV</given-names></name>
<etal/>
</person-group>. <article-title>Alveolar-arterial oxygen gradients versus the Neonatal Pulmonary Insufficiency Index for prediction of mortality in ECMO candidates</article-title>. <source>J Pediatr Surg</source> <year>1984</year>; <volume>19</volume>: <fpage>380</fpage>–<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr15-0267659112457970">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stolar</surname><given-names>CJ</given-names></name>
<name><surname>Dillon</surname><given-names>PW</given-names></name>
</person-group>. <article-title>Extracorporeal membrane oxygenation for neonatal respiratory failure</article-title>. <source>Surg Annu</source> <year>1987</year>; <volume>19</volume>: <fpage>111</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr16-0267659112457970">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muntean</surname><given-names>W</given-names></name>
</person-group>. <article-title>Coagulation and anticoagulation in extracorporeal membrane oxygenation</article-title>. <source>Artif Organs</source> <year>1999</year>; <volume>23</volume>: <fpage>979</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr17-0267659112457970">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansell</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Extracorporeal membrane oxygenation for perinatal and paediatric patients</article-title>. <source>Respir Care</source> <year>2003</year>; <volume>48</volume>: <fpage>352</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr18-0267659112457970">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skogby</surname><given-names>M</given-names></name>
<name><surname>Friberg</surname><given-names>LG</given-names></name>
<name><surname>Adrian</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Pharmacological inhibition of plasma coagulation and platelet activation during experimental long-term perfusion</article-title>. <source>Scand Cardiovasc J</source> <year>2003</year>; <volume>37</volume>: <fpage>222</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr19-0267659112457970">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grasselli</surname><given-names>G</given-names></name>
<name><surname>Pesenti</surname><given-names>A</given-names></name>
<name><surname>Marcolin</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Percutaneous vascular cannulation for extracorporeal life support (ECLS): a modified technique</article-title>. <source>Int J Artif Organs</source> <year>2010</year>; <volume>33</volume>: <fpage>553</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr20-0267659112457970">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Foley</surname><given-names>DS</given-names></name>
<name><surname>Swaniker</surname><given-names>F</given-names></name>
<name><surname>Pranikoff</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Percutaneous cannulation for paediatric venovenous extracorporeal life support</article-title>. <source>J Pediatr Surg</source> <year>2000</year>; <volume>35</volume>: <fpage>943</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr21-0267659112457970">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reickert</surname><given-names>CA</given-names></name>
<name><surname>Schreiner</surname><given-names>RJ</given-names></name>
<name><surname>Bartlett</surname><given-names>RH</given-names></name>
<etal/>
</person-group>. <article-title>Percutaneous access for venovenous extracorporeal life support in neonates</article-title>. <source>J Pediatr Surg</source> <year>1998</year>; <volume>33</volume>: <fpage>365</fpage>–<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr22-0267659112457970">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vats</surname><given-names>A</given-names></name>
<name><surname>Pettignano</surname><given-names>R</given-names></name>
<name><surname>Culler</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Cost of extracorporeal life support in paediatric patients with acute respiratory failure</article-title>. <source>Crit Care Med</source> <year>1998</year>; <volume>26</volume>: <fpage>1587</fpage>–<lpage>1592</lpage>.</citation>
</ref>
<ref id="bibr23-0267659112457970">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>F</given-names></name>
<name><surname>Khan</surname><given-names>S</given-names></name>
<name><surname>Talor</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Evaluation of two paediatric polymethyl pentene membrane oxygenators with pulsatile and non-pulsatile perfusion</article-title>. <source>Perfusion</source> <year>2011</year>; <volume>26</volume>: <fpage>229</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr24-0267659112457970">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>F</given-names></name>
<name><surname>Clark</surname><given-names>JB</given-names></name>
<name><surname>Kunselman</surname><given-names>AR</given-names></name>
<etal/>
</person-group>. <article-title>Hemodynamic evaluation of arterial and venous cannulae performance in a simulated neonatal extracorporeal life support circuit</article-title>. <source>Perfusion</source> <year>2011</year>; <volume>26</volume>: <fpage>276</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr25-0267659112457970">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Byrnes</surname><given-names>J</given-names></name>
<name><surname>McKamie</surname><given-names>W</given-names></name>
<name><surname>Swearingen</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Hemolysis during cardiac extracorporeal membrane oxygenation: a case-control comparison of roller pumps and centrifugal pumps in a paediatric population</article-title>. <source>ASAIO</source> <year>2011</year>; <volume>57</volume>: <fpage>456</fpage>–<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr26-0267659112457970">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colby</surname><given-names>CE</given-names></name>
<name><surname>Sheehan</surname><given-names>A</given-names></name>
<name><surname>Benitz</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400</article-title>. <source>J Extra Corpor Technol</source> <year>2003</year>; <volume>35</volume>: <fpage>35</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr27-0267659112457970">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malviya</surname><given-names>S</given-names></name>
</person-group>. <article-title>Monitoring and management of anticoagulation in children requiring extracorporeal circulation</article-title>. <source>Semin Thromb Hemost</source> <year>1997</year>; <volume>23</volume>: <fpage>563</fpage>–<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr28-0267659112457970">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sievert</surname><given-names>A</given-names></name>
<name><surname>Uber</surname><given-names>W</given-names></name>
<name><surname>Laws</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Improvement in long-term ECMO by detailed monitoring of anticoagulation: a case report</article-title>. <source>Perfusion</source> <year>2011</year>; <volume>26</volume>: <fpage>59</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr29-0267659112457970">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khaja</surname><given-names>WA</given-names></name>
<name><surname>Bilen</surname><given-names>O</given-names></name>
<name><surname>Lukner</surname><given-names>RB</given-names></name>
<etal/>
</person-group>. <article-title>Evaluation of heparin assay for coagulation management in newborns undergoing ECMO</article-title>. <source>Am J Clin Pathol</source> <year>2010</year>; <volume>134</volume>: <fpage>950</fpage>–<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr30-0267659112457970">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pantalos</surname><given-names>GM</given-names></name>
<name><surname>Horrell</surname><given-names>T</given-names></name>
<name><surname>Merkley</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>In vitro characterization and performance testing of the tension cardiopulmonary assist system</article-title> <source>ASAIO</source> <year>2009</year>; <volume>55</volume>: <fpage>282</fpage>–<lpage>286</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>